Medios AG: Medios AG moves to the Prime Standard stock exchange segment

DGAP-News: Medios AG / Key word(s): Regulatory Approval
29.05.2020 / 12:58
The issuer is solely responsible for the content of this announcement.

Press Release

Medios AG moves to the Prime Standard stock exchange segment

Berlin, 29 May 2020 – Medios AG, one of the leading Specialty Pharma companies in Germany, was today admitted to the sub-segment of the Regulated Market with additional post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange. Thus, the Medios shares are now traded in the segment with the highest transparency and disclosure requirements in Europe. Previously, Medios was listed in the General Standard of the Regulated Market.

Matthias Gärtner, CFO of Medios AG: ‘With the move to the Prime Standard, Medios fulfils the prerequisite for the admission into a selection index of Deutsche Börse. An inclusion in the SDAX would significantly increase the visibility of Medios and the attractiveness of the share for investors.’

By mid-May 2020, Medios had already achieved an important interim goal on its way to an SDAX inclusion as a result of the successful placement of 600,000 existing shares. The shares had been sold to international institutional investors in a private placement. Free float meanwhile increased from 57% to above 62%, in particular as a result of the placement, contributing to an improved liquidity of the stock.

——————-

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany’s first publicly listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8, DE000A288821) are listed in the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.


29.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this